This book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the findings that have already emerged. Coverage extends to antipsychotics, antidepressants and mood stabilizing, cognitive-enhancing and anxiolytic drugs. The volume also examines the interface of pharmacogenetics with substance dependence and brain imaging, and considers its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore an essential reference for all clinicians and researchers involved.